VASCULAR THERAPIES - Key Persons
Andrew Midler founded Savitr Capital LLC in 2008, a privately owned investment company which invests in emerging and innovative technology driven companies. Savitr Capital is currently invested in a portfolio of innovation leaders focused in health care and industrial manufacturing. Mr. Midler currently serves on the board of directors of Druggability Technologies, Glytec Systems, CellMDX, Emerald Bio Agriculture, Ancora Heart, BioIQ, and Vascular Therapies. In the majority of these Savitr is a large shareholder and participates at the Board level.
Previously, Mr. Midler founded Standard Pacific Capital in 1995. The investment management firm launched with $75m of assets and grew to over $5 billion and a team of 100 people by 2005. Mr. Midler managed the firm's Global Long/Short Equity Fund until 2005, Standard Pacific's flagship product. He also supervised the firm's Credit Opportunities, Commodity, Quantitative, and Japan Long/Short Equity strategies. He served as the firm's CIO and CEO from 1995 until December 2007. In December of 2007, he sold his majority ownership interest in the firm. Prior to founding Standard Pacific, he served as the director of equity portfolio management at CS First Boston, a global institutional money management firm. Previously, he managed a significant portion of the global hedge fund Odyssey Partners. From 1986 through 1993, he worked at Fidelity Investments and his tenure included assignments as portfolio manager of the Fidelity Convertible Securities Fund, Fidelity Equity Income II Fund, and Fidelity Growth & Income Fund. He holds an MBA from Harvard Business School and MA and BA degrees in Political Science from Stanford University.
Job Titles:
- Managing Director of Spring Bay Ventures
Daniel M. Ryan is Managing Director of Spring Bay Ventures, a single-family office in Ponte Vedra Beach, Florida. Since 2003, Mr. Ryan has managed Spring Bay's venture portfolio, which consists of a range of early stage privately held businesses, primarily in healthcare. Mr. Ryan is responsible for sourcing and executing investment transactions and then assisting portfolio companies achieve their aims through his board membership engagement.
Prior to Spring Bay, Mr. Ryan served for 14 years in a range of senior executive capacities for Unison Industries, a leading supplier of engineered electro-mechanical components for the aviation industry. Over this period, Unison revenues grew from $10 to $200 million leading to its acquisition by General Electric in 2002.
Mr. Ryan holds a B.S. and M.S. in Mechanical Engineering from Purdue University and a M.B.A. from Duke University. Dan also serves as a board member of The Sontag Foundation, The Brain Tumor Network and The Divine Mercy House.
Gerald Dorros, M.D., an interventional cardiologist and cardiovascular interventionist, has been the Medical Director of the William Dorros-Isadore Feuer Interventional Cardiovascular Disease Foundation in Scottsdale, Arizona, and Milwaukee, Wisconsin since 1983. He has also served as Director of Cardiology at the Arizona Heart Hospital and at St. Luke's Medical Center in Milwaukee. He joined the Arizona Heart Institute Foundation, Phoenix, Arizona in 1997 and served as its President from 1997 to 2000. He was the third U.S. physician to perform coronary angioplasty in the United States (1978), the first cardiologist to perform peripheral vascular interventions (1979), the principal author of the first manuscript detailing the complications associated with PTCA, and a founding member of the National Heart, Lung and Blood Institute's PTCA Registry. He has had multiple university faculty appointments, has taught and performed live demonstrations of both coronary and peripheral vascular interventions throughout the world, and has authored or co-authored more than 250 peer reviewed journal articles, as well as numerous textbook chapters. Dr. Dorros' entrepreneurial experience has included involvement with more than 50 medical device companies, including co-founding Arterial Vascular Engineering. (AVE subsequently bought by Medtronic) and Power Medical Interventions, as well as recent Director Positions at BioCardia, Vascular Imaging Corporation, and Windmill Cardiovascular Systems.
John McDermott joined Vascular Therapies as of January 2019 as Chief Executive Officer. Mr. McDermott has over 30 years of senior executive management, sales, marketing, and finance experience in the vascular industry. From 2008 to 2018 he served as the CEO of Endologix, a public company that is a developer of aortic stent grafts. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard's vascular surgery and endovascular businesses.
Prior to that, he served for four years as President of C.R. Bard's division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard.
Mr. McDermott holds a B.S. in Finance from Arizona State University and an M.B.A from Western International University.
Job Titles:
- Vice President of Quality Assurance
Maureen is responsible for developing and maintaining Vascular Therapies' Quality Systems and ensuring compliance with domestic and international GMPs and ISO directives and guidelines.
Trained as a scientist, Maureen is an expert in the areas of quality assurance, GMP auditing, compliance and liquid/parenteral formulation development. She has held leadership roles in globally respected pharmaceutical and biopharmaceutical research companies, including Pfizer, Wyeth and Agouron Pharmaceuticals.
Prior to joining Vascular Therapies, Maureen was Director of Pharmaceutical Sciences Quality Assurance, Quality Systems and Compliance at Pfizer, where she authored, trained and maintained the company's Pharmaceutical Sciences Quality Plan and was responsible for the oversight and operation of its Governance Model.
Maureen holds several U.S. patents, including liquid and parenteral formulations of Sirolimus. She earned her B.S. in Biochemical Science from the University of Vermont.
Job Titles:
- Vice President of New Product Development
With 20 years of experience in new product and process development in the medical device, drug delivery, and specialty chemicals fields, Paul manages and leads all aspects of VT's product development, CMC, and technical operations.
Prior to joining Vascular Therapies in 2008, Paul was a Program Manager at Arsenal Capital Partners (a leading New York-based private equity firm). Before working with Arsenal, he was a Staff Engineer at Cordis Corporation (a Johnson & Johnson company) developing drug-device combination products, including drug-eluting stents and bioabsorbable drug delivery systems. He brings a wealth of technical and strategic organizational skills to Vascular Therapies, as well as a deep understanding of medical device and pharmaceutical quality systems and regulatory requirements.
Paul graduated from Bucknell University with a B.A. in Liberal Arts and a B.S. in Chemical Engineering and earned his Ph.D. in Chemical Engineering from Princeton University.
Job Titles:
- Vice President of Clinical Affairs
Rakesh joined Vascular Therapies in 2007 and heads VT's global clinical development programs. He is also responsible for maintaining the companies IT infrastructure and has worked to align technology initiatives with business goals.
During a 20-year career that has covered both pharmaceutical and medical device industries, Rakesh has held leadership roles in companies ranging from large pharma to start-up ventures and has successfully managed several regulatory filings including three NDAs.
Prior to joining Vascular Therapies, he was Project Leader at Cordis Corporation (a Johnson & Johnson company) where he led clinical research activities for complex global studies. He holds a B.A. in Biology from Cornell University.
Robert Croce joined VT's Board of Directors following a 36 year career at Johnson & Johnson where he held a series of senior positions, culminating with 12 years as Company Group Chairman. Previously, he was Worldwide Franchise Chairman of Cordis, a Johnson & Johnson company.
Job Titles:
- President of Clark Enterprises, Inc
Robert Flanagan is President of Clark Enterprises, Inc. ("CEI"), a privately held corporation with diverse assets in real estate, private equity and financial markets. Since 1989, Mr. Flanagan has spearheaded the expansion of CEI beyond construction and real estate, successfully launching CNF Investments, the private equity division of CEI that focuses on life sciences, oil and gas and technology investing. Mr. Flanagan currently serves on the boards of Eagle Oil & Gas Co., Brown Advisory, Svelte Medical Systems and is Chairman of the Board of Directors of Sagent Pharmaceuticals (NASDAQ:SGNT). He is Chairman of the Board of Directors of Washington's Federal City Council, is a Trustee of Clark Charitable Foundation, and a member of the Board of Advisors of Georgetown University's McDonough School of Business. Mr. Flanagan previously served on the Board of Directors of Clark Construction Group, LLC through 2015; was Chairman of the Board of Directors of Martek Biosciences Corporation (NASDAQ:MATK) and was Treasurer, Secretary and a member of the Board of Directors of Baltimore Orioles, Inc.
Mr. Flanagan received a BS in Business Administration from Georgetown University, an MST from the American University School of Business and is a Certified Public Accountant licensed in Washington, DC.
Job Titles:
- Senior Director of Manufacturing
Ron graduated from Rochester Institute of Technology with a Bachelor of Technology in Mechanical Engineering and earned his Master of Science in Engineering Management from Florida International University.
Job Titles:
- Employee
- Vice President of Operations
Rosanne joined the company in 2005 as its first employee. She has been responsible for developing and implementing the company's operational infrastructure, including financial and accounting systems, supply chain and purchasing, human resource and employee benefits, and project management functions.
Previously, Rosanne was Director of Marketing for Datascope Corporation where she managed the vascular closure and interventional products business unit. Prior to Datascope, she was Global Marketing Manager at Cordis Corporation (a Johnson & Johnson company) where she successfully launched a new stent product that addressed a significant gap in the product portfolio. Earlier in her career she was Business Unit Manager for Peritoneal Dialysis at National Medical Care, a subsidiary of W.R. Grace & Co.
Rosanne earned her nursing diploma from the Englewood Hospital School of Nursing and is a registered nurse in the state of New Jersey. She graduated with honors from St. Peter's University with a B.S. in Health Care Management.
Job Titles:
- FSCAI CHIEF SCIENTIFIC OFFICER / FOUNDER
- Physician‑Scientist
Sriram Iyer ("Sri") is a physician‑scientist and an entrepreneur with a proven track record of translating ideas and patents to products useful in clinical practice. Since founding Vascular Therapies in 2001 he has provided leadership and strategic input for all operational, product development and financing activities of the company.
An interventional cardiologist and vascular medicine specialist with more than 25 years of experience in coronary, peripheral vascular and carotid interventions, he served as the Associate Chairman of the Department of Cardiology and the Director of Peripheral Vascular and Carotid Interventions at Lenox Hill Hospital in New York City. Sri is recognized worldwide for his pioneering work and contributions to angioplasty and stenting for treatment of extra‑cranial carotid artery disease. A gifted teacher, he has mentored and trained several cardiologists, many of whom are now directors and department heads in hospitals in the US and abroad.
His experience as an investigator in several FDA regulated clinical trials has provided a solid understanding of the rigor and the regulatory expectations surrounding product approval. Sri has published extensively and holds several patents including methods for treating failure of hemodialysis vascular accesses and vascular grafts. He is a Fellow of the American College of Cardiology (FACC), a Fellow of the Society for Cardiac Angiography and Interventions (FSCAI) and received his M.B; B.S.; M.D. (General Medicine) and D.M. (Cardiology) degrees from the University of Bombay, India.